Loreen Straub

Loreen Straub

Auto-generated profile, based on publicly available information

Loreen Straub

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
SHSonia Hernández-Díaz
Sonia Hernández-Díaz
LSLoreen Straub
Loreen Straub
BBBrian T. Bateman
Brian T. Bateman
YZYanmin Zhu
Yanmin Zhu
HMHelen Mogun
Helen Mogun
KHKrista F. Huybrechts
Krista F. Huybrechts
Maternal use of valproate during pregnancy has been associated with an increased risk of neurodevelopmental disorders in children. Although most studies of other antiseizure medications have not shown increased risks of these disorders, there are limited and conflicting data regarding the risk of autism spectrum disorder associated with maternal topiramate use. We identified a population-based cohort of pregnant women and their children within two health care utilization databases in the United States, with data from 2000 through 2020. Exposure to specific antiseizure medications was defined on the basis of prescription fills from gestational week 19 until delivery. Children who had been exposed to topiramate during the second half of pregnancy were compared with those unexposed to any antiseizure medication during pregnancy with respect to the risk of autism spectrum disorder. Valproate was used as a positive control, and lamotrigine was used as a negative control. The estimated cumulative incidence of autism spectrum disorder at 8 years of age was 1.9% for the full population of children who had not been exposed to antiseizure medication (4,199,796 children). With restriction to children born to mothers with epilepsy, the incidence was 4.2% with no exposure to antiseizure medication (8815 children), 6.2% with exposure to topiramate (1030 children), 10.5% with exposure to valproate (800 children), and 4.1% with exposure to lamotrigine (4205 children). Propensity score-adjusted hazard ratios in a comparison with no exposure to antiseizure medication were 0.96 (95% confidence interval [CI], 0.56 to 1.65) for exposure to topiramate, 2.67 (95% CI, 1.69 to 4.20) for exposure to valproate, and 1.00 (95% CI, 0.69 to 1.46) for exposure to lamotrigine. The incidence of autism spectrum disorder was higher among children prenatally exposed to the studied antiseizure medications than in the general population. However, after adjustment for indication and other confounders, the association was substantially attenuated for topiramate and lamotrigine, whereas an increased risk remained for valproate. (Funded by the National Institute of Mental Health.).

5 January 2022 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
LSLoreen Straub
Loreen Straub
BBBrian T. Bateman
Brian T. Bateman
SHSonia Hernandez-Diaz
Sonia Hernandez-Diaz
CYCassandra York
Cassandra York
BLBarry Lester
Barry Lester
KHKrista F. Huybrechts
Krista F. Huybrechts
Neurodevelopmental disorders (NDDs) are characterized by deficits in the development of the central nervous system that can affect a child’s memory, language, motor function, and ability to learn, socialize, and maintain self-control. They frequently co-occur and may be associated with severe impairments of functioning in adulthood. Neurodevelopmental disorders are clinically diagnosed by evaluating the presence of aberrant behaviors or delays in achieving developmental milestones and by comparing such behaviors with those of children of the same age, sex, and culture.1

28 March 2022 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
LSLoreen Straub
Loreen Straub
SHSonia Hernández-Díaz
Sonia Hernández-Díaz
BBBrian T. Bateman
Brian T. Bateman
KWKatherine L. Wisner
Katherine L. Wisner
KGKathryn J. Gray
Kathryn J. Gray
KHKrista F. Huybrechts
Krista F. Huybrechts
Antipsychotic medications are among the most commonly prescribed drug classes in the US.1 The clinical uses of antipsychotic drugs extend beyond psychotic disorders and include bipolar, major depressive, and anxiety disorders, all of which are common among women of childbearing age.2 This expansion of approved and off-label indications, coupled with unimpaired fecundity with newer prolactin-sparing agents, has produced a more than doubling of antipsychotic drug use during pregnancy in the 2000s.3,4 Antipsychotic drugs are highly lipophilic and cross the placenta.5 While the risks of congenital malformations and short-term neonatal complications associated with in utero exposure to antipsychotic drugs have been evaluated by epidemiologic studies,6-12 little information is available on human neurodevelopmental teratogenicity despite animal data suggesting a potential neurotoxic effect.13

15 October 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
LSLoreen Straub
Loreen Straub
BBBrian T. Bateman
Brian T. Bateman
SHSonia Hernandez‐Diaz
Sonia Hernandez‐Diaz
CYCassandra York
Cassandra York
YZYanmin Zhu
Yanmin Zhu
KHKrista F. Huybrechts
Krista F. Huybrechts

23 January 2024 in Neurology
Verified
Journal Article
Closed access
JCJacqueline M. Cohen
Jacqueline M. Cohen
SASilje Alvestad
Silje Alvestad
ESElizabeth A. Suarez
Elizabeth A. Suarez
ASAndrea Schaffer
Andrea Schaffer
RSRandi M. Selmer
Randi M. Selmer
KFKari Furu
Kari Furu
Valproate should be avoided in pregnancy, but it is the most effective drug for generalized epilepsies. Alternative treatment may require combinations of other drugs. Our objectives were to describe first trimester use of antiseizure medication (ASM) combinations that are relevant alternatives to valproate and determine whether specific combinations were associated with a lower risk of major congenital malformations (MCM) compared with valproate monotherapy. We conducted a population-based cohort study using linked national registers from Denmark, Finland, Iceland, Norway, and Sweden and administrative health care data from the United States and New South Wales, Australia. We described first trimester use of ASM combinations among pregnant people with epilepsy from 2000 to 2020. We compared the risk of MCM after first trimester exposure to ASM combinations vs valproate monotherapy and low-dose valproate plus lamotrigine or levetiracetam vs high-dose valproate (≥1,000 mg/d). We used log-binomial regression with propensity score weights to calculate adjusted risk ratios (aRRs) and 95% CIs for each dataset. Results were pooled using fixed-effects meta-analysis. Among 50,905 pregnancies in people with epilepsy identified from 7.8 million total pregnancies, 788 used lamotrigine and levetiracetam, 291 used lamotrigine and topiramate, 208 used levetiracetam and topiramate, 80 used lamotrigine and zonisamide, and 91 used levetiracetam and zonisamide. After excluding pregnancies with use of other ASMs, known teratogens, or a child diagnosed with MCM of infectious or genetic cause, we compared 587 exposed to lamotrigine-levetiracetam duotherapy and 186 exposed to lamotrigine-topiramate duotherapy with 1959 exposed to valproate monotherapy. Pooled aRRs were 0.41 (95% CI 0.24-0.69) and 1.26 (0.71-2.23), respectively. Duotherapy combinations containing low-dose valproate were infrequent, and comparisons with high-dose valproate monotherapy were inconclusive but suggested a lower risk for combination therapy. Other combinations were too rare for comparative safety analyses. Lamotrigine-levetiracetam duotherapy in first trimester was associated with a 60% lower risk of MCM than valproate monotherapy, while lamotrigine-topiramate was not associated with a reduced risk. Duotherapy with lamotrigine and levetiracetam may be favored to treat epilepsy in people with childbearing potential compared with valproate regarding MCM, but whether this combination is as effective as valproate remains to be determined. This study provides Class II evidence that in people with epilepsy treated in the first trimester of pregnancy, the risk of major congenital malformations is lower with lamotrigine-levetiracetam duotherapy than with valproate alone, but similar with lamotrigine-topiramate.

22 December 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
LSLoreen Straub
Loreen Straub
KHKrista F. Huybrechts
Krista F. Huybrechts
HMHelen Mogun
Helen Mogun
BBBrian T. Bateman
Brian T. Bateman
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder that affects social skills, communication, and behavior control, encompassing a variety of symptoms and severity levels. While its etiology remains unknown, there is some evidence suggesting that—apart from its inheritable component1—the perinatal period is critical for developing ASD.2 A recently published cohort study including more than 147 000 singleton children, of whom approximately 74% were delivered after epidural analgesia, reported a 37% increase in risk of having a child with ASD among those with epidural analgesia exposure during labor.3 It was hypothesized that epidural analgesics could alter the normal course of brain maturation, potentially through placental transfer of local anesthetics.4